News & Events

Xplico participates in international congresses and events 6-8 times a year in Europe and the US, so there are plenty of opportunities to meet up with us.

We would be delighted to give you a presentation of our products and services and/or to discuss your specific needs.


BIO-Europe Spring 2019, Vienna, Austria, March 25-27, 2019

Please meet us at the 2019 BIO-Europe Spring Partnering Conference in Vienna, Austria. With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe. (January 2019)

Bio International Convention, Philadelphia, USA, June 3-6, 2019

Please meet us at the BIO International Convention in Philadelphia in June 2019. The key benefits of attending the Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders and unparalleled networking opportunities with 16,000+ attendees from 74 countries. (January 2019)

Xplico named a "Gazelle Company" for the 3rd year in a row

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2018 Gazelle Company (a growth company) for the 3rd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years. (December 2018)

Publication of the Xplico Valuation Survey

In July and August 2018 Xplico conducted a survey among 600 industry professionals about valuation in the life science industry and received 79 responses. We hereby present the results of the survey.
(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article


(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview


(June 2018)